文献速递认知障碍与痴呆脑血管病

降脂治疗与阿尔茨海默病风险:孟德尔随机化研究

Lipid lowering and Alzheimer disease risk: A mendelian randomization study.
PubMed 文献 · Ann Neurol · 2020-01-01

该研究采用孟德尔随机化方法,利用HMGCR、PCSK9、NPC1L1和APOB基因变异评估降脂药物靶点对阿尔茨海默病(AD)风险的影响。结果未发现他汀类、依折麦布或米泊美生相关靶点对AD风险有保护作用,但遗传预测的PCSK9抑制剂暴露与AD风险增加相关(每标准差LDL-C降低的合并OR=1.45,95%CI 1.23-1.69)。

要点

  • 他汀类、依折麦布和米泊美生的遗传模拟未显示对AD风险有影响。
  • PCSK9抑制剂遗传模拟与AD风险增加相关(OR=1.45,95%CI 1.23-1.69)。
  • 使用PCSK9抑制剂的患者可能需要药物警戒监测AD风险。

核心结论

  • 遗传证据不支持他汀类、依折麦布或米泊美生用于AD预防的重新定位。
  • 遗传预测的PCSK9抑制剂暴露可能增加AD风险,尽管该效应弱于其对冠心病的保护作用。

研究设计与样本

  • 采用孟德尔随机化分析,使用编码HMGCR、PCSK9、NPC1L1和APOB的基因变异。
  • 变异按LDL-C关联加权,数据来自脂质遗传学联盟(n最高达295,826)。
  • 对两个大样本的AD风险孟德尔随机化估计进行荟萃分析(总计n=24,718例病例,56,685例对照)。

主要发现

  • HMGCR、APOB和NPC1L1模型未提示相关降脂药物类别会影响AD风险。
  • 遗传模拟的PCSK9抑制剂暴露预测在两个AD样本中均增加AD风险(每标准差LDL-C降低的合并OR=1.45,95%CI=1.23-1.69)。

临床怎么用

  • 对于使用PCSK9抑制剂的患者,可考虑关注AD相关症状的监测。
  • 不推荐基于遗传证据将他汀类、依折麦布或米泊美生用于AD预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether genetic variation affecting the expression or function of lipid-lowering drug targets is associated with Alzheimer disease (AD) risk, to evaluate the potential impact of long-term exposure to corresponding therapeutics. METHODS: We conducted Mendelian randomization analyses using variants in genes that encode the protein targets of several approved lipid-lowering drug classes: HMGCR (encoding the target for statins), PCSK9 (encoding the target for PCSK9 inhibitors, eg, evolocumab and alirocumab), NPC1L1 (encoding the target for ezetimibe), and APOB (encoding the target of mipomersen). Variants were weighted by associations with low-density lipoprotein cholesterol (LDL-C) using data from lipid genetics consortia (n up to 295,826). We meta-analyzed Mendelian randomization estimates for regional variants weighted by LDL-C on AD risk from 2 large samples (total n = 24,718 cases, 56,685 controls). RESULTS: Models for HMGCR, APOB, and NPC1L1 did not suggest that the use of related lipid-lowering drug classes would affect AD risk. In contrast, genetically instrumented exposure to PCSK9 inhibitors was predicted to increase AD risk in both of the AD samples (combined odds ratio per standard deviation lower LDL-C inducible by the drug target = 1.45, 95% confidence interval = 1.23-1.69). This risk increase was opposite to, although more modest than, the degree of protection from coronary artery disease predicted by these same methods for PCSK9 inhibition. INTERPRETATION: We did not identify genetic support for the repurposing of statins, ezetimibe, or mipomersen for AD prevention. Notwithstanding caveats to this genetic evidence, pharmacovigilance for AD risk among users of PCSK9 inhibitors may be warranted. ANN NEUROL 2020;87:30-39.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Williams DM, Finan C, Schmidt AF, et al. Lipid lowering and Alzheimer disease risk: A mendelian randomization study. Ann Neurol. 2020. PMID: 31714636. doi:10.1002/ana.25642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。